Arcturus Collaborated with CSL to Develop and Commercialize Self-amplifying mRNA Vaccines
Shots:
- Arcturus will receive $200M up front, ~$1.3B in development milestones & ~$3B in commercial milestones & is also eligible to receive a 40% net profit share for COVID-19 vaccine products along with royalties
- CSL Seqirus get the rights to use Arcturus’ self-amplifying mRNA technology to support the research, development, manufacture, and commercialization of vaccines for COVID-19, influenza, and pandemic preparedness along with other globally prevalent respiratory infectious diseases along with lead development & commercialization of vaccines
- The collaboration combines Arcturus’ self-amplifying mRNA vaccine & LUNAR delivery platform technologies with CSL’s world-leading capabilities as a commercial-scale manufacturer and global distributor of influenza & pandemic vaccines
Ref: Businesswire | Image: Arcturus
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
